Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10044552HBVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS10052789HBVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS30073184HIVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS44024288HTLV-1ENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TCGA Plot Options
Drug Information
GeneAR
DrugBank IDDB01128
Drug NameBicalutamide
Target IDBE0000132
UniProt IDP10275
Regulation Typeantagonist
PubMed IDs10076535; 10500149; 10754148; 11931851; 12517791; 11752352
CitationsWang LG, Liu XM, Kreis W, Budman DR: Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33.@@Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C: Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11173-7.@@Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA: Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology. 1999 Oct;54(4):745.@@Bouchal J, Kolar Z, Mad'arova J, Hlobilkova A, von Angerer E: The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP. Biochem Pharmacol. 2002 Mar 15;63(6):1177-81.@@Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003 Jan 1;63(1):149-53.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
GroupsApproved
Direct ClassificationTrifluoromethylbenzenes
SMILESCC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
Pathways
PharmGKBPA164746255
ChEMBLCHEMBL409